A comparison of fentanyl, droperidol, and morphine

Gorodeizky, C. W.; Martin, W R

doi:10.1002/cpt196566731

Cited by 23 publications

(3 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Included in these studies was administration of 3 doses of the compound GPA-2087, the results of which have been published separatelyY The drugs were administered under double-blind conditions according to a latin square design, with intervals of one week or longer between drug administrations. The drug effects were assessed with changes in pupil size with the use of our standard photographic method, 5 subjects' and observers' singledose opiate questionnaires, 4 • 15 and a subjective drug-effect questionnaire 10 containing items from the morphine-benzedrine group scale ( MBG), pentobarbital-chlorpromazine-alcohol group scale ( PCAG), and LSD-specific group scale (LSD) of the Addiction Research Center Inventory ( ARCI). On each test day control pupil -o All doses in this study were given on a milligram per kilogram basis in relation to a 70 Kg.…”

Section: Methodsmentioning

confidence: 99%

Evaluation of nalbuphine for abuse potential

Jasinski

Mansky

1972

Clin Pharma and Therapeutics

106

View full text Add to dashboard Cite

National Institute of Mental Health, Addiction Research Center, United States Department of Health, Education, and Welfare, Public Health Service, Health Services and Mental Health AdministrationNalbuphine ( EN-2234A) is structurally related to the potent analgesic oxymorphone and the potent narcotic antagonist naloxone (Fig. 1). Nalbuphine differs by the cyclobutylmethyl substitution on the nitrogen and the reduction of the oxygen in the 6-position to a hydroxyl group. Blumberg" demonstrated in animals that nalbuphine is a narcotic antagonist which is % to 1fs as potent as nalorphine. As an analgesic, nalbuphine is 4 to 5 times as potent as morphine in the mouse and rat phenylquinone writhing test but shows only weak analgesic activity in the mouse hot-plate test. In withdrawn morphine-dependent monkeys, nalbuphine does not suppress but exacerbates abstinence and in nonwithdrawn morphine-dependent monkeys, nalbuphine is

show abstract

Section: Methodsmentioning

confidence: 99%

Evaluation of nalbuphine for abuse potential

Jasinski

Mansky

1972

Clin Pharma and Therapeutics

106

View full text Add to dashboard Cite

show abstract

“…Codeine is often prescribed in combination with nonsteroidal anti-inflammatory drugs, such as acetaminophen, aspirin, and ibuprofen, to treat varying degrees of pain, and was the most common drug used in the world in 2013 [3]. The extreme potency of fentanyl, ~100 times that of morphine [4], makes it ideal for smuggling across borders, as only a small amount represents a substantial payout. For example, 250 pounds were seized at the Mexican border in January 2019 [5], and was valued at ~$3.5 million with the potential of killing >50 million people [6].…”

Section: Introductionmentioning

confidence: 99%

Quantitative Measurements of Codeine and Fentanyl on a Surface-Enhanced Raman-Active Pad

et al. 2019

View full text Add to dashboard Cite

The USA is in the midst of an opioid crisis that included over 60,000 overdose fatalities in 2017, mostly unintentional. This is due to excessive use of prescription opioids and the use of very strong synthetic opioids, such as fentanyl, mixed with illicit street drugs. The ability to rapidly determine if people or packages entering the country have or contain drugs could reduce their availability, and thereby decrease the use of illicit drugs. In an effort to address this problem, we have been investigating the ability of surface-enhanced Raman spectroscopy to detect trace amounts of opioids on clothing and packages. Here, we report the measurement of codeine and fentanyl at 100 ng/mL for 5 min on a pad impregnated with gold colloids, as well as a preliminary measurement of 500 pg of fentanyl on a glass surface using one of these pads. The calculated limit of detection for this measurement was 40 pg. This data strongly suggests that these pads, used with portable Raman analyzers, would be invaluable to airport security, drug raids, crime scenes, and forensic analysis.

show abstract

“…Subjective effects were measured with subjects' and observers' singledose opiate questionnaires 6 and items from the Morphine Benzedrine Group Scale (MBG), 8 Changes in pupillary diameter were determined photographically. 7 Each test day, control pupil photographs were obtained at 8:00 and 8:30 A.M. Drugs were administered at 9 A.M. Subjective effects and pupillary changes were assessed at 9:30, 10:00, 11:00 A.M., 12:00 noon, and 1:00, 2:00, and 9 P.M. abstinence was determined by the 24-hr substitution procedures in 4 subjects made dependent on 30 mg of morphine administered subcutaneously at 6:00 and 10:00 A.M. and 4:00 and 10:00 P.M. (120 mg daily).…”

Section: Subjective Effects and Miosis Etorphinementioning

confidence: 99%

Etorphine in man. I. Subjective effects and suppression of morphine abstinence

Jasinski

Griffith

Carr

1975

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

The effects of etorphine, a potent morphine-like drug, were qualitatively and quantitatively compared to those of morphine. In nondependent subjects, etorphine in doses of 0.025, 0.050, and 0.100 mg produced pupillary constriction and morphine-like subjective effects and euphoria. Etorphine was 500 times as potent as morphine, with a very rapid onset and short duration of action. In morphine-dependent subjects, etorphine suppressed abstinence but for a shorter period than morphine. These studies indicate that in man etorphine is a morphine-like drug with a high abuse potential.

show abstract

A comparison of fentanyl, droperidol, and morphine

Cited by 23 publications

References 3 publications

Evaluation of nalbuphine for abuse potential

Evaluation of nalbuphine for abuse potential

Quantitative Measurements of Codeine and Fentanyl on a Surface-Enhanced Raman-Active Pad

Etorphine in man. I. Subjective effects and suppression of morphine abstinence

Contact Info

Product

Resources

About